Search results for: Multi-Indication Medicines
Filter search results
New OHE Consulting Report on Shaping Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
18 April 2016
…new medicines to recommend for use in the NHS, and the direction of future research in this area. The study, written by OHE’s Sarah Karlsberg Schaffer, Patricia Cubi-Molla, Nancy Devlin…
Two New Publications: ‘New Age Decision Making in HTA’ and ‘How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty?’
6 September 2016
…to the inclusion of multiple criteria in HTA. She discussed the potential merits of structured decision making and explained that there is a growing interest in this topic globally, providing…
OHE at HTAi 2018
29 May 2018
…Shah will join Rachel Baker and Ailsa Brown on this panel to reflect on empirical findings and raise questions for evidence-based policy on the provision of end of life medicines….
Presentations from ISPOR and HTAi 2018
12 July 2018
…of Health Economics From evidence to action when people disagree: societal values and provision of end of life medicines from Office of Health Economics Developing a value set…
New Publication: Advanced Therapy Medicinal Products and Health Technology Assessment
12 October 2018
…outcomes-based contracts. For discount rates, an international, multi-disciplinary forum should be established to consider the economic, social and ethical implications of the choice of rate. Finally, consideration of the feasibility…
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision
8 October 2020
…they need to be. The time for multi-stakeholder action to recognise and reward the broader value of vaccines and other healthcare interventions is now (Brassel et al. 2020a; Brassel et al.,…
Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic
21 April 2021
…The SC should ensure that the European Commission, the European Medicines Agency, and the Member States’ (MSs) healthcare agencies coordinate via the European Network for Health Technology Assessment (EuNetHTA), so…
Would Waiving COVID-19 Vaccines Patents Save Lives?
18 May 2021
…to increase manufacturing supply capacity, building on a report by leaders of these bodies setting out the challenges. Public-private partnerships between Governments, multilateral organisations, donors and private firms, including patent…
Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
16 June 2021
…to go beyond a sector-specific focus to evaluate options that generate disparate outcomes spanning multiple sectors, the importance of which has been amply demonstrated by COVID-19 and measures to contain…